Elevating Dermatological Drug Development Through Advanced Inflammatory Marker Targeting Methodology
Time: 11:00 am
day: Day One
Details:
• Speaking to preclinical study design to evaluate anti-interleukin 17 NanoAbs as a treatment for plaque psoriasis, which showed the downregulation of psoriasis molecular markers
• Leveraging 3D biologic skin models to mimic the structure of human skin to suggest NanoAbs’ therapeutic potential
• Demonstrating the potential for a systemic novel approach with higher affinity for IL-17F isoform to improve treatment efficacy for patients with psoriasis
